The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: Results of a preliminary study

World Journal of Urology

Volumn 21, Issue 1, 2003, Pages 37-42

  Tyrrell, C J ^a   Blake, G M ^b   Iversen, P ^c   Kaisary, A V ^d   Melezinek, I ^e  

^a Plymouth Oncology Centre   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Hormonal therapy; Osteoporosis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANILIDE; ANTINEOPLASTIC AGENT; BICALUTAMIDE;

AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MALE; MULTICENTER STUDY; ORCHIECTOMY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; BONE DENSITY; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0141924097     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-003-0322-7     Document Type: Article

References (33)

1. Benmalek A, Sabatier JP (1998) Comparison and cross-calibration of DXA systems: ODX-240 and Sophos L-XRA versus Hologic QDR-4500 for spinal bone mineral measurement. Translation of a reference database. Osteoporos Int 8:570-577
2. Broulik PD, Stárka L (1997) Effect of antiandrogens Casodex and epitestosterone on bone composition in mice. Bone 20:473-475
3. Calero JA, Diaz-Curiel M, de al Piedra C (1999) Bicalutamide (Casodex) treatment does not produce bone effects in male Wistar rats. J Bone Min Res 14 (Suppl 1):S220
4. Congress of the United States (1993) Hip fracture outcomes in people aged 50 and over: mortality, service use, expenditures and long-term functional impairment. Washington DC. Office of Technology Assessment, Congress of the United States. US Department of Commerce publication NTIS PB94107653
5. Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-289
6. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A):12S-19S
7. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181-186
8. Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444
9. De Laet CEDH, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1998) Hip fracture risk in elderly men and women: validation in the Rotterdam study. J Bone Min Res 13:1587-1593
10. Diamond T, Campbell J, Bryant C, Lynch W (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561-1566
11. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston S, Reeve J, Reid DM, Russell RG, Stevenson JC (1998) Management of male osteoporosis: report of the UK Consensus Group. Q J Med 91:71-92
12. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C (1994) Universal standardization of dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Min Res 9:1503-1514
13. Hanson J (1997) Standardization of femur BMD. J Bone Min Res 12:1316-1317
14. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I (2000) Bicalutamide ('Casodex') 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years' follow-up. J Urol 164:1579-1582
15. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Eisman JA (1995) A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol 22:932-936
16. Kelly TL (1990) Bone mineral density reference databases for American men and women. J Bone Min Res 5 (Suppl 1): S249
17. Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P (1997) Incidence and direct medical costs of hospitalisations due to osteoporotic fractures in Switzerland. Osteoporos Int 7:414-425
18. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CCJr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489
19. Lunar DPX Series Operator's Manual (1998) Lunar Corporation, Madison
20. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Masaryk P, Pols HA, Poor G, Reid DM, Scheidt-Nave C, Weber K, Varlow J, Kanis JA, O'Neill TW, Silman AJ (1997) Bone density variation and its effect on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS study. J Bone Min Res 12:1883-1894
21. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C (1999) Bone mineral density in men treated with synthetic gonadotrophin- releasing hormone agonists for prostatic carcinoma. J Urol 161:1219-1222
22. Melton LJ (1995) Epidemiology of fractures. In: Riggs BL, Melton LJ (eds) Osteoporosis: etiology, diagnosis and management, 2nd edn. Lippincott-Raven, Philadelphia, pp225-247
23. Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. J Bone Min Res 13:1915-1923
24. Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA (1995) Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporosis Int 5:427-432
25. Ray NF, Chan JK, Thamer M, Melton LJ3rd (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Min Res 12:24-25
26. Sieber PR, Keiller DL, Kahnoski RJ, Garcia-Vargas JE, Gallo J, McFadden S (2002) Bone mineral density is maintained during bicalutamide ('Casodex') treatment. Proc Am Soc Clin Oncol 21:196a
27. Steiger P (1995) Standardization of spine BMD measurements. J Bone Min Res 10:1602
28. Suzuki Y, Oishi Y, Aikawa K, Wada T, Yamazaki H, Hasegawa N, Aoki H, Shiono Y, Takasaka S, Akazawa K, Shibuya M, Onishi T, Yoshino Y (1999) The risk of osteoporosis after androgen deprivation in patients with prostatic carcinoma. J Urol 161 (Suppl 89): Abstract 1141
29. Townsend MF, Sanders WH, Northway RO, Graham SDJr (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545-550
30. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G (1998) A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33:447-456
31. Vœhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, Mattelaer J, D'Hulster D, Mahler C (1994) Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrin 41:525-530
32. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54:607-611
33. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. World Health Organization, Geneva